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Results of Screening a Large Group of Intercollegiate Competitive
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BARRY J. MARON, MO, FACC,* SACAREO A. BODISON, MO,t YVONNE E. WESLEY,*
EBEN TUCKER, MO,* KIMBERLY J. GREEN, BS*
Bethesda and College Park, Maryland
To determine the feasibility of detecting cardiovascular
disease in a large group of young competitive athletes,
a prospective screening evaluation of intercollegiate stu-
dent athletes was undertaken at the University of Mary-
land. Initial clinical screening (including personal and
family history, physical examination and 12 lead elec-
trocardiogram) was performed in 501 athletes. Ninety
of these subjects had positive findings on one or more
of the three studies and agreed to further cardiologic
evaluation. The vast majority (75 [84%] of 90) had no
definitiveevidence of cardiovascular disease, although 1
athlete had mild systemic hypertension and 14 (15%)
had echocardiographic evidenceof relatively mild mitral
valve prolapse that had not been previously suspected.
In three athletes with relatively mild ventricular septal
hypertrophy (14to 15 mm), it was not possibleto discern
The highly conditioned competitive athlete epitomizes the
most healthy segment of our society. Nevertheless, occa-
sionally youthful (or older) competitive athletes may die
suddenly , often during athletic activity (1-9). Because such
catastrophes are totally unexpected, they convey a partic-
ularly tragic and alarming connotation to the community .
Previous studies (1,2) have shown that sudden death in
young athletes is due to covert cardiovascular disease in the
vast majority of instances, usually a congenital malforma-
tion of the heart or great arteries and most commonl y hy-
pertrophic cardiomyopathy. Consequ ently, there has been
increasing interest in defining procedure s by which those
athletes at risk for sudden death due to cardiovascular dis-
ease can be prospectively identified before such catastrophes
occur (10).
It has been estimated (11) that > 25 million children and
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with absolute certainty whether the wall thickening was
a manifestation of hypertrophic cardiomyopathy or sec-
ondary to athletic conditioning ("athlete heart").
Therefore, this screening protocol identified no ath-
letes with definite evidence of hypertrophic cardio-
myopathy, Marfan's syndrome or other cardiovascular
diseases that convey a significant potential risk for sud-
den death or diseaseprogression during athletic activity.
This failure to identify such diseases could have been
due to a lack of sensitivity of the screening tests or to
the low frequency with which these diseases occur in
youthful healthy athletes. A systematic preparticipation
screening program (such as the present one) does not
appear to be an efficient means of detecting clinically
important cardiovascular disease in young athletes.
(J Am Coll CardioI1987;10:1214-21)
young adults participate in organized competitive athletic
activities in the United States annually. Hence, it is obviou s
that a periodic individualized and comprehensive medical
examination for each participant in organized sports is be-
yond the capabilities of the current medical care system.
Although programs designed to screen large numbers of
athletes for cardiovascular disease have been attempted spo-
radically, such examinations have varied considerably in
approach and design and are frequently superficial and de-
signed only to fulfill a perceived legal requirement. Indeed ,
it remains to be determined whether the screening of large
groups of athletes for cardiovascular disease is a practical
or cost-efficient endeavor. For this reason , the present pro-
spective screening study was conducted in a large and well
defined group of youthful intercollegiate athletes.
Methods
Study design. The University of Maryland in College
Park , Maryland is a member of the National Collegiate
Athletic Association (Division I), with a large and successful
intercollegiate athletic program involving about 500 to 600
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male and female athletes during each academic year. All
student athletes are asked by the University to undergo an
annual evaluation at the University Health Center to deter-
mine their medical fitness for competition.
Students who expressed an interest in participating in an
intercollegiate sport between September 1984 and June 1985
were evaluated and constitute the present study group. Initial
evaluation at the University Health Center included: I) per-
sonal and family history, 2) physical examination (including
blood pressure determination), and 3) 12 lead scalar elec-
trocardiogram (ECG). History and physical examination were
performed by at least one of the three clinicians who are
permanent members of the Health Center staff. Athletes who
expressed a positive response to the history or showed an
alteration on the physical examination or ECG (Table 1)
were referred to the Cardiology Branch of the National
Institutes of Health for a noninvasive cardiovascular eval-
uation (including M-mode and two-dimensional echocardi-
ography, history, physical examination, ECG and chest ra-
diograph).
Characterization of study group. A total of 540 ath-
letes constituted the initial study group. However, 27 ath-
letes refused to participate in the protocol and 12 others
disclosed that they had previously undergone a noninvasive
cardiologic evaluation (including echocardiography) by a
private physician of their choice. Hence, 50 I athletes par-
ticipated in the preparticipation screening evaluation and
constituted the final study group. Athletes ranged in age
from 17 to 30 years (mean 19.3); 357 (71%) were men.
The majority were white (381 [76%]); 114 (23%) were
black, and 6 (I %) were Asian or Hispanic. They were in-
volved in 14 sports, although football contributed the largest
number (152 [30%]) (Table I).
Echocardiography. An Advanced Technology Labo-
ratory (ATL) Mark 500 mechanical sector scanner with a 3
MHz transducer was used to perform the two-dimensional
echocardiographic studies. Images of the heart were ob-
tained in a number of cross-sectional planes, using standard
transducer positions (12). M-mode echocardiograms were
recorded with a dedicated Irex System II ultrasound unit
equipped with a 2.25 MHz transducer, or were derived from
the two-dimensional image under direct anatomic visual-
ization.
Methods for imaging the ventricular septum and posterior
left ventricular free wall with M-mode echocardiography
have been described previously (13,14). Ventricular septal
thickness was measured at the onset of the R wave of the
ECG at the cross-sectional level where wall thickness was
maximal; thickness of the posterior free wall was measured
during the same phase of the cardiac cycle and at the same
level. Other cardiac dimensions were assessed according to
the criteria of the American Society of Echocardiography
(14).
Mitral valve echograms were recorded with M-mode
echocardiography using an ultrasound window at the left
sternal border (usually the third intercostal space) with the
transducer perpendicular to the anterior chest wall and mitral
valve. A late systolic or pansystolic (nadir in mid-systole)
displacement 2:3 mm of one or both mitral leaflets posterior
to the line of mitral leaflet coaptation connecting its closure
(C) and opening (D) points was regarded as evidence of
mitral valve prolapse (15-17). On the two-dimensional
echocardiogram, mitral prolapse was considered to be pres-
ent if portions of the mitral leaflets were displaced during
systole beyond the plane of the mitral anulus (superiorly
into the left atrium) on the parasternal long-axis view or on
both the long-axis and apical four chamber views (18-20).
A qualitative judgment was made regarding overall valve
size and leaflet thickening or redundancy.
ECG. The standard 12 lead ECG was performed utiliz-
ing a Burdick EK-5A instrument with the patient in the
supine position during quiet respiration. The ECG was con-
sidered abnormal if one or more of the criteria detailed in
Table 2 were achieved.
Table 1. Distribution of Sports Participated in by SOl Intercollegiate Athletes
No. of Athletes No. (%) Referred
rfr of Overall for Cardiovascular
Sport Male Female Total Group Evaluation
Football 152 () 152 30 29 (32%)
Track and field/cross-country 51 33 84 18 22 (25%)
Lacrosse 38 20 58 II 8 (9%)
Soccer 43 () 43 8 12 (13%)
Field hockey 0 34 34 7 5 (6%)
Wrestling 24 () 24 5 3 (3%)
Basketball II 12 23 4 5 (6%)
Swimming and diving 12 II 23 4 1(\%)
Tennis 6 9 15 3 3 (3%)
Gymnastics () 14 14 3 0(0%)
Volleyball () II II 2 1(1%)
Baseball II () II 2 1(1%)
Golf 9 () 9 2 0(0%)
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Table 2. Criteria for a Positive History, Physical Examination and 12 Lead Electrocardiogram
History (personal and family)
I. Prior denial of medical approval for athletic participation, military service or life insurance
2. Occurrence of any of the following during the last 5 years
Near fainting, fainting or "blacking out"
Chest pain, pressure or discomfort occurring more than once
Irregular heartbeat or palpitation
Shortness of breath or fatigue out of proportion to the degree of exertion undertaken
3. Prior identification of elevated blood pressure
4. Prior medical illness requiring a physician's care and lasting> I week (depending on circumstance)
5. Close relative (parent, sibling, aunt, uncle or grandparent) who experienced a "heart attack," disabling
cardiovascular disease or sudden death before 50 years of age
Physical examination
I. Grade '2:2/6 systolic murmur
2. Any diastolic murmur
3. Second heart sound single or widely split and fixed with respiration
4. Elevated brachial blood pressure (> 145/90 mm Hg on two or more readings)
5. Findings suggestive of mitral valve prolapse (mid-systolic click or late systolic murmur)
6. Irregular heart rhythm
7. Physical features suggestive of Marfan's syndrome*
Electrocardiogram
I. R wave '2:30 mm in lead V5 or V6 or in a standard lead
2. S wave 2:30 mm in lead VI or V2
3. ST segment depression or T wave flattening or inversion in two or more leads
4. Abnormal Q wavest
5. PR interval '2:0.25 or <0.12 second
6. Second or third degree atrioventricular block
7. Leftt or right§ atrial enlargement
8. QRS frontal plane axis deviation: right axis '2: 1200 and left axis 2:300
9. Prolonged QT interval (corrected for heart rate) (21)
10. Right or left bundle branch block or Rsr' pattern in lead VI or V2
II. Premature ventricular complexes
*These features included: I) greater than average height for age with excessively long and thin limbs (arm
span exceeding height); 2) looseness and hyperextensibility of joints; 3) arachnodactyly; 4) history of visual
problems; 5) sparsity of subcutaneous fat: 5) pectus carinatum or excavatum. tQ (or QS) waves were considered
abnormal if 2:0.04 second in duration or 2:3 mm deep and were present in two or more leads (Q or QS waves
present only in leads V1 and V2 were not considered abnormal). :j:Left atrial enlargement was diagnosed if the
product of the depth and duration of the negative portion of the P wave in lead VI was greater than -0.03.
§Right atrial enlargement was diagnosed if P waves in leads II and III or V, were peaked and 2:2.5 mV in
amplitude.
Results
Screening protocol. The results of the preparticipation
screening protocol are summarized in Figure I, Of the 501
study subjects, 102 had positive findings on one or more of
the initial screening studies (history, physical examination
and ECG); 83 athletes had alterations on one study alone
(ECG, 57; physical examination, 16; history, 10) and 19
had alterations on two studies (physical examination and
ECG, 6; history and ECG, 8; history and physical exami-
nation, 5). Of these 102 athletes, 12 chose not to cooperate
further with the protocol, but the remaining 90 athletes (75
men and 15 women) underwent noninvasive cardiologic
evaluation and testing (including echocardiography) and,
therefore, constitute the final study subset. Abnormal phys-
ical findings, positive responses to the personal and family
history and ECG alterations in these 90 athletes are sum-
marized in Table 3.
Athletes referred for noninvasive evaluation. Of the
90 athletes referred for evaluation, 75 showed no definitive
evidence of cardiovascular disease, and had normal left
ventricular wall thickness (::512 mm) (Fig, 2). Six of these
75 athletes had incidental echocardiographic findings that
were considered to be of little or no clinical relevance,
including 2 with a prominent right ventricular muscle band
(moderator band) and 3 with left ventricular bands (false
tendons); the latter structures were identified on parasternal
long-axis or apical four chamber views as thin and discrete
linear echoes evident throughout the cardiac cycle within
the cavity extending from the mid-portion of the ventricular
septum to the free wall (or papillary muscles) (22,23). One
other athlete demonstrated chaotic motion of a small portion
of the distal mitral valve apparatus, which had the appear-
ance of a ruptured chorda tendinea, but this was not asso-
ciated with mitral valve prolapse or regurgitation.
Three of these 75 athletes without definitive evidence of
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Total No. Athletes
Figure l. Flow diagram showing results of the preparticipation
screening investigation for a cohort of competitive intercollegiate
athletes studied at the Universityof Maryland. C-V = cardiovas-
cular;HCM = hypertrophic cardiomyopathy; MVP = mitralvalve
prolapse.
cardiovascular disease showed a mild increase in ventricular
septal thickness of 14 to 15 mm that was confined to the
anterior and basal portion of septum; the left ventricular free
wall was of normal thickness (~12 mm); septal to posterior
free wall thickness ratio was 1.2 in 2 of these athletes and
I .5 in the other. These findings were associated with left
atrial enlargement (42 to 48 mm) in all three athletes; left
ventricular end-diastolic dimension was normal in two (47
and 52 mm) and increased in one (58 mm) and each had a
normal end-systolic dimension (31 to 38 mm). Systolic an-
terior motion of the mitral valve was absent in all three
athletes. Each of the three athletes with septal thickening
had been referred for noninvasive evaluation because of a
soft systolic ejection murmur, but had a negative family
history for heart disease and a normal ECG.
Fourteen (15%) of the 90 athletes had echocardiographic
evidence of relatively mild mitral valve prolapse, demon-
strated by M-mode echocardiography alone in 4, by two-
dimensional echocardiography alone in 2 and by both tech-
niques in 8; the pattern of prolapse was pansystolic in each
of the 12 athletes in whom it was identified by M-mode
echocardiography. In 13 of the 14 athletes, the mitral valve
leaflets were thin and pliable; only 1 had a true anatomic
abnormality in which the valve appeared to be increased in
size and the leaflets thickened and redundant. Two of the
14 athletes had auscultatory findings suggestive of prolapse
(mid-systolic click), but none had evidence of mitral re-
Discussion
Sudden death in athletes. Previous studies (1-3) have
documented that sudden unexpected death may occur oc-
casionally in young competitive athletes. Such catastrophes,
although uncommon, are usually due to congenital cardio-
vascular disease (most commonly hypertrophic cardio-
myopathy), but also to anomalies of the coronary arteries
or a ruptured aorta as a manifestation of Marfan' s syndrome
(1,2). These findings have stimulated physicians concerned
with the medical care of athletes to consider methods whereby
such cardiovascular diseases might be detected before ca-
tastrophes occur (10). Such information would make it pos-
sible to withdraw selected athletes from the potentially high
risk circumstances of competitive athletics (27),
Limitations of preparticipation screening. There are
many potential problems that make it difficult to establish
successful and economically feasible large-scale screening
gurgitation on the basis of the auscultatory or Doppler ex-
amination. Only 1 of the 14 athletes with echocardiographic
evidence of mitral valve prolapse reported cardiac symptoms
that potentially were manifestations of mitral prolapse syn-
drome (that is, chest pain, syncope, dyspnea).
One athlete had a history of systemic hypertension and
proved to have relatively mild elevation in blood pressure
on physical examination (140 to 155/90 to 100 mm Hg).
In each of the 90 athletes referred for noninvasive car-
diovascular evaluation, it was possible to identify by two-
dimensional echocardiography the origin of the left main
coronary artery in its proper anatomic position (emanating
from the left sinus of Valsalva) and thereby exclude an
anomalous origin of the left coronary artery from the anterior
sinus of Valsalva (24).
Cardiac dimensions obtained with M-mode echocardi-
ography in the 90 athletes are summarized in Table 4. No
athlete showed an increase in transverse aortic dimension.
Left atrial, right ventricular and left ventricular end-diastolic
dimensions for the group were typical of trained athletes
(25,26). Several showed increased cavity dimensions, in-
cluding 16 (18%) with a left ventricular end-diastolic di-
mension of 56 to 61 mm, II (12%) with a left atrial size
of 41 to 48 mm and II (12%) with a right ventricular
dimension of 31 to 38 mm. In each athlete, chest radiographs
showed no cardiac or pulmonary abnormalities.
Athletes evaluated noninvasively outside the study
protocol. Twelve university athletes (not in the group of
SOl) had been examined for cardiovascular disease by a
private physician before the present screening study was
initiated. A noninvasive evaluation including echocardi-
ography showed no evidence of cardiovascular disease in
11 of the 12, whereas the other athlete proved to have
systemic hypertension (blood pressure 1801130 mm Hg).
Normal
Uncertain
Refused
Non-Invasive
Evaluation
C-V Disease
Absent
MVP HCM
(echo) Not
Excluded
Hyper-
tension
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programs for the purpose of identifying cardiovascular dis-
ease in asymptomatic individuals. Truly comprehensive
community-based screening is probably impractical because
it would essentially require each athlete to undergo a non-
invasive cardiologic evaluation. Given the large number of
participants in intercollegiate athletic programs, all but the
least expensive screening effort would be beyond the fi-
nancial resources of most institutions. Hence, the present
study constitutes an attempt to design a simple, practical
and inexpensive protocol that might be readily applicable
to other scholastic or collegiate settings for the purpose of
detecting those cardiovascular diseases known to cause sud-
den death or produce significantmorbidity in young athletes.
Such diseases include hypertrophic cardiomyopathy and
Marfan's syndrome, but also other congenital cardiac dis-
eases and systemic hypertension.
Design and findings of present screening protocol.
With these priorities in mind, the present protocol was struc-
tured to rely initially on the personal and family history,
physical examination and 12 lead ECG. Because echocardi-
ography was not used as an initial screening test in this
study, we cannot be certain of its utility in a large group of
asymptomatic young athletes. Intuitively, we would have
expected echocardiography to enhance our sensitivity for
the detection of certain cardiovascular abnormalities (such
as hypertrophic cardiomyopathy and aortic dilation) (28,29);
however, this test would also have been prohibitively ex-
pensive and generally impractical for the study of >500
athletes. The stress exercise ECG would also have important
limitations as a primary screening test because of its ex-
pense, the high frequency with which a false positive ST
segment response occurs in athletes (30) and the fact that
Figure2. Echocardiographic and electrocardiographic (ECG) studies
obtained in a 20 year old male football player. A, M-mode echo-
cardiogram shows normal ventricular septal (VS) and posterior
free wall (PW) thickness and mild enlargement of the left ven-
tricular (LV) diastolic dimension. B, Abnormal 12lead ECG show-
ing deep Q waves in leads II, III and aVF and deep S wave in
lead V2. C, Stop-frame two-dimensional echocardiogram (in di-
astole at mitral valve level) in the parasternal short-axis view
showing normal left ventricular wall thickness. D, Two-dimen-
sional echocardiogram (in diastole) in parasternal long-axis view
showing normal anterior ventricular septal (VS) and posterior free
wall thickness. Two-dimensional echocardiograms are accompa-
nied byschematic drawings; calibrationdots andlinesare 10mm
apart. AML = anterior mitral leaflet; Ao = aorta; LA = left
atrium; LAT. FW = lateral free wall; MV = mitral valve; Post.
FW = posterior free wall; RV = right ventricle.
coronary heart disease is very uncommon in young athletes
(1,2,31).
In this investigation of >500 intercollegiate athletes, we
identified no athlete with definitive evidence of cardiovas-
cular disease of major clinical consequence (with the pos-
sible exception of I individual with relatively mild systemic
hypertension). However, in 3 of those 90 athletes who were
referred for further testing, hypertrophic cardiomyopathy
could not be excluded with certainty on the basis of the
echocardiographic findings. Each of these individuals had
a mildly increased left ventricular wall thickness of 14 to
15 mm confined to the anterior portion of the ventricular
septum (in the absence of systolic anterior motion of the
mitral valve and evidence of obstruction to left ventricular
outflow). Hence, although echocardiographic findings in
these three athletes resembled a mild morphologic expres-
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Table 3. Positive Family and Personal History and Electrocardiographic (ECG) Alterations in
90 Athletes Referred for Cardiovascular Evaluation
Positive Physical Positive Positive ECG
Examination Family History Personal History Alterations
(24 athletes) (7 athletes) (13 athletes)* (65 athletes)'
Systolic murmur 19 Marfan's syndrome I Chest pain 8 LVHt 42
Systolic click 2 Premature death 6 Near syncope I Symmetric T wave I
Irregular rhythm 3 or "heart attack" Syncope I inversion
Heart murmur 2 Other ST-T 18
Exertional dyspnea 3 Rsr'VIN, 16
Irregular heartbeat 3 LAE 6
Hypertension 2t Q waves 6
LAD 5
RBBB 2
PYCs I
'Some athletes had more than one abnormality; four other athletes with an abnormal ECG on initial screening
are not included in this analysis because they did not participate in the noninvasive cardiovascular evaluation.
tBased on increased voltages (that is, R wave in lead Ys or Y6 or in a standard lead 2:30 mm or S wave in
lead V1 or V2 2:30 mm. :j:Systemic hypertension was not verified on subsequent examinations in one of these
athletes.
LAD = left axis deviation; LAE = left atrial enlargement; LVH = left ventricular hypertrophy; Pv'Cs =
premature ventricular complexes; RBBB = right bundle branch block.
sion of nonobstructive hypertrophic cardiomyopathy (25,32),
these dimensions were also consistent with the "physio-
logic" form of left ventricular hypertrophy induced by ath-
letic training ("athlete heart") (25,26). Ideally, we would
have preferred to study the families of these athletes for
hypertrophic cardiomyopathy (with echocardiography) (33)
or to repeat their echocardiograms after a period of decon-
ditioning to determine whether regression of hypertrophy
occurred (25,34,35). However, it was not possible to obtain
such studies, which could possibly have aided in distin-
guishing hypertrophic cardiomyopathy from the athlete heart.
Fifteen percent of our athletes who were referred for
cardiovascular evaluation and studied with echocardiog-
raphy had evidence of relatively mild mitral valve prolapse.
However, detection of mitral prolapse in a group of young
athletes probably does not, in itself, justify a major screening
program. Mitral prolapse is a generally benign entity, the
risk for disease progression or sudden death is extremely
low (36) and, hence, even its identification very rarely re-
Table 4. M-Mode Echocardiographic Dimensions in 90
Intercollegiate Athletes
Variable
Ventricular septal thickness (mm)
Posterior free wall thickness (mm)
Septal/free wall thickness ratio
LV diastolic dimension (mm)
Aortic root dimension (mm)
Left atrial dimension (mrn)
Right ventricular dimension (mm)
LV = left ventricular.
Mean
10.5
10.1
1.0
50.9
29.1
35.5
24.2
Range
7 to 15
7 to 14
0.7 to 1.5
41 to 61
21 to 35
26 to 48
12 to 38
quires disqualification of the athlete from competition (36).
Indeed, to date, there have been only three reported occur-
rences of sudden death associated with exertion in patients
with mitral valve prolapse (36) and only one of these was
in a trained competitive athlete (36,37).
Limitations of presentscreening study. There are sev-
eral possible explanations for the fact that we found little
major cardiovascular disease in the course of this investi-
gation. First, it is possible that the expected prevalence of
such disease in a group of young athletes is so low as to
make its detection unlikely in a study of this size. For
example, diseases such as hypertrophic cardiomyopathy and
Marfan's syndrome are relatively rare (probably <0.5% of
a group of young athletes) (38) and, therefore, could be
expected to be found only once or twice, or not at all, in a
group of 500 subjects.
Second, our screening program (which initially relied on
history, physical examination and ECG) may not have been
sensitive enough to identify some of those cardiovascular
diseases that we had hoped to detect. For example, the
frequency and nature of clinical abnormalities in patients
with congenital anomalies of the coronary arteries (that is,
anomalous origin of the left coronary artery from the anterior
sinus of Valsalva) have not been fully established and, there-
fore, the utility of the ECG as a screening test for such
diseases is largely unknown (l,2,24). On the other hand,
because approximately 90 to 95% of patients with hyper-
trophic cardiomyopathy (39,40) (including those at risk for
sudden death [41]) have an abnormal 12 lead EeG. the vast
majority of athletes with this disease should have been iden-
tified by our screening protocol.
The ECG also has limitations with respect to specificity
for the identification of left ventricular hypertrophy (42,43)
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and cardiovascular disease (44). In particular, a wide variety
of ECG alterations are known to occur commonly in trained
athletes (45-49), many of which may mimic those abnor-
malities observed in patients with structural heart disease.
Indeed, almost 15% of the athletes in this study met our
criteria for an abnormal ECG, but ultimately proved to have
no evidence of underlying cardiovascular disease. Of note,
the number of such "false positive" results will be influ-
enced largely by the particular criteria arbitrarily assigned
to define an abnormal ECG; for example, had we used QRS
voltage 2::25 mm as a criterion for abnormality, we would
have substantially increased the absolute number of abnor-
mal ECGs, the vast majority of which would have repre-
sented additional false positive results.
The history and physical examination also have intrinsic
limitations as screening tests for cardiovascular disease in
a group of young athletes. For example, whereas the phys-
ical examination could be expected to detect virtually all
patients with aortic valve stenosis because of the charac-
teristic loud heart murmur, most patients with hypertrophic
cardiomyopathy would not be identifiedby examination alone
because the majority of patients with this disease have its
nonobstructive form and, therefore, have a soft heart mur-
mur or none at all (33,50).
Another possible limitation concerns the relatively small
subset of 27 athletes (constituting 5% of the overall screen-
ing cohort) who refused to participate in the protocol. It is
possible that these athletes did not cooperate with the study
because they suspected or knew that they had cardiovascular
problems. On the other hand, such iack of compliance is a
well recognized risk of undertaking any large population
study. Unfortunately, neither the University of Maryland
nor the clinical investigators involved could actually require
from the student athletes absolute cooperation with the
screening protocol.
Conclusions. Designing a practical, cost-efficient and
effective approach for the mass screening of large groups
of young athletes is a formidable task. The present screening
program initially utilizing history, physical examination and
the 12 lead ECG identified no individuals with definitive
evidence of cardiovascular diseases known to cause sudden
death in young athletes, such as hypertrophic cardio-
myopathy or Marfan's syndrome with aortic dilation (al-
though 15% of those ultimately referred for echocardiog-
raphy had evidence of relatively mild mitral valve prolapse).
These results may be explained by the low frequency with
which many cardiovascular diseases occur in a group of
young athletes or by the lack of sensitivity on the part of
our screening protocol, or both. Inclusion of the ECG as a
primary screening test did not appear to appreciably enhance
the sensitivity of an informed history and physical exami-
nation in detecting important cardiovascular disease, and it
was also responsible for a large number of false positive
observations.
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